If you've been on semaglutide, tirzepatide, or any other GLP-1 medication — or you're considering starting one — you've probably seen the phrase "Ozempic eyes" somewhere online. It's a confusing mix of real research and social media alarm, and I get asked about it in the chair often enough that it's worth untangling properly.
Here's the honest version: there is a real, rare eye risk associated with semaglutide that's worth knowing about. There is also a lot of noise that overstates it. Both things are true at once.
The finding that started the conversation
In 2024, researchers at Mass Eye and Ear and Harvard Medical School published a retrospective cohort study in JAMA Ophthalmology looking at patients prescribed semaglutide for either diabetes or weight management. They found that patients prescribed semaglutide had a meaningfully higher rate of a condition called nonarteritic anterior ischemic optic neuropathy, or NAION, compared to patients prescribed other medications for the same conditions.
NAION is a sudden, painless loss of vision in one eye caused by reduced blood flow to the optic nerve. It's rare, it's not reversible, and until this study, it hadn't been strongly linked to GLP-1 medications. The study found the increased risk was more pronounced in patients being treated for diabetes than in those using semaglutide purely for weight loss, though both groups showed elevated risk compared to non-users.
That's a real signal, published in a serious journal, and it's reasonable for both patients and prescribers to take it seriously. It does not mean semaglutide causes blindness in most people who take it. NAION remains rare overall, and this was an observational study, which can show an association without proving that the drug directly causes the condition.
What about diabetic retinopathy?
This is the other question I get, usually from patients who are diabetic and already have some retinopathy: does starting a GLP-1 drug make it worse?
The evidence here is more reassuring, and it's actually been studied more thoroughly. A 2023 systematic review and meta-analysis published in Clinical Drug Investigation, which pooled data from 20 randomized, placebo-controlled trials covering nearly 25,000 patients with type 2 diabetes, found that GLP-1 receptor agonists were not associated with an increased risk of diabetic retinopathy overall. That's a fairly large and well-controlled body of evidence pointing the same direction.
There is a separate, older phenomenon worth knowing about: when blood sugar drops quickly after starting any effective diabetes treatment — insulin, GLP-1 drugs, or otherwise — patients can experience a short-term worsening of existing retinopathy before things stabilize. This is a known effect of rapid glycemic improvement generally, not something unique to semaglutide, but it's part of why we like to see patients around the time they start a new diabetes medication.
What I actually recommend
I'm not in the business of telling patients to stop a medication that's working for them, and for most people, the benefits of GLP-1 drugs for blood sugar control, weight, and cardiovascular risk are substantial. What I do recommend is straightforward:
Get a baseline dilated eye exam before or shortly after starting a GLP-1 medication, especially if you have diabetes or any existing retinal disease. This gives us a clear picture of your retina and optic nerve before treatment, so if anything changes later, we have something to compare it to.
Know the warning sign for NAION: sudden, painless vision loss or dimming in one eye. This is different from gradual blur or fluctuating vision — it tends to be sudden and noticeable, often on waking. If this happens, it's an emergency. Call an eye doctor immediately or go to urgent care; time matters for ruling out other causes of sudden vision loss.
Keep up with regular diabetic eye exams if you have diabetes, regardless of what medication you're on. This was already the standard of care before GLP-1 drugs existed, and it remains the single best way to catch retinopathy changes early, whatever is driving them.
None of this is a reason to panic about a medication that may be genuinely improving your health. It's a reason to keep your eye doctor in the loop when your medication list changes — which, honestly, is good practice with any new prescription, not just this one.
Thinking about your eye health?
I see patients at Eye & Health in the East Village, and I'm happy to talk through what a baseline exam looks like if you're starting or already on a GLP-1 medication. You can book online — usually within the week.
This is not medical advice. Please consult your eyecare professional or schedule an eye appointment today.
